Short answer
Niagen Bioscience, Inc. (NAGE) filed its Q3 2025 10-Q quarterly report on Nov 4, 2025 for the quarter ended Sep 30, 2025. Quarterly revenue was $34M (up 32.9% year over year) with net income of $5M.
Q3 2025 key financials · XBRL
- Revenue
- $34M
- +32.9% YoY · +9.2% QoQ
- Net income
- $5M
- +143.8% YoY · +26.8% QoQ
- Operating margin
- 12.5%
- Gross margin
- 64.5%
- EPS (diluted)
- $0.05
- +66.7% YoY · +25.0% QoQ
Source: XBRL data from the Niagen Bioscience, Inc. (NAGE) Q3 2025 10-Q on SEC EDGAR. USD.
Niagen Bioscience, Inc. Q3 2025 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- Q3 revenue $33.986M, up 33% YoY from $25.580M
- Gross margin 64.5% vs 63.5% YoY; net income $4.578M vs $1.878M
- Best segment Consumer Products revenue $26.017M, up 44%; worst Analytical revenue $772K, down 2%
- Cash $64.3M, including $64.1M unrestricted; approximately $33.6M inventory purchase commitment through September 2026
- Outlook: cash sufficient for at least twelve months; possible additional capital needs thereafter
Risk Factors
- No newly identified risk factor; quarter-end disclosure reiterates risks from the Annual Report
- Regulatory competition risk; FDA determined NMN may lawfully be marketed as a dietary ingredient
- Product concentration risk; future success largely depends on Tru Niagen® sales
- Supply-chain risk; single supplier W.R. Grace provides NRC
- Liquidity risk; $64.3 million cash and no borrowings under $10.0 million credit line at September 30, 2025
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other Niagen Bioscience, Inc. quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.